Tag: mantle cell lymphoma

AACR 2015: Lymphoma Abstract Highlights

The annual American Association of Cancer Research (AACR) concluded last Wednesday in Philadelphia. Lymphoma related abstracts from researchers at the Meyer Cancer Center at Weill Cornell Medical College, presented results that could lead to potential new lymphoma therapies. These included:

Longitudinal genomic and transcriptomic analysis of mantle cell lymphoma in a targeted combination trial of a selective CDK4/6 inhibitor

In this study researchers from the Meyer Cancer Center used whole exome sequencing (WES) and whole transciptome sequencing (WTS) to study the progression of mantle cell lymphoma in patients, who had previously taken part in a clinical trial testing the combination of palbociclib and bortezomib. The primary goal was to understand the difference in response caused by genetic differentiations in those patients who responded to treatment and patients who did not respond to treatment. Investigators sought to understand these genetic differentiations by identifying copy number variants, single nucleotide variants, and differentially expressed genes. In doing so they were able to identify molecular clues to the mechanisms of resistance presented in patients with mantle cell lymphoma. These results are being followed up with in functional studies. They could potentially offer greater insight into the treatment of patients with mantle cell lymphoma.

Transcriptome sequencing of the Reed-Sternberg cells of classical Hodgkin lymphoma

Genomic studies of classical Hodgkin lymphoma (cHL) have been confined to cell lines due to the technological difficulties in isolating Hodgkin and Reed-Sternberg cells from reactive background tissue. However, a multi-disciplinary research team found a solution to the issues involved in isolating these cells. A flow cytometric cell isolation method allowed for the isolation of thousands of viable HRS cells from cHL tumors, which enabled the isolation of high quality RNA from HRS cells and intra-tumor B cells from 9 primary cases of cHL.  The team also sequenced the transcriptomes of four cell lines, and conducted a search for activated pathways. In the future, this form of analysis of HRS cells will allow for the expanded study of cHL pathogenesis. This line of analysis could potentially lead to new individualized approaches to therapy through the identification of altered signaling pathways.

Dr. Jia Ruan Speaks about Novel Therapeutic Combinations for Mantle Cell Lymphoma

In a segment taken from the 2014 meeting of the American Society of Hematology (ASH), Dr. Jia Ruan answered questions about the difficulties faced in treating patients with mantle cell lymphoma and the novel therapeutic combinations that could help improve treatment.

The video can be seen here.

New Clinical Trial: Open-label, Phase 2 Study of ACP-196 in Subjects with Mantle Cell Lymphoma

The Weill Cornell Lymphoma Program has recently opened a new clinical trial for men and women with mantle cell lymphoma. The study sponsor is Acerta Pharma BV, and the principal investigator at Weill Cornell is Peter Martin, M.D.. For more information about the study, please call Amelyn Rodgriguez, RN at (212) 746-1362 or e-mail Amelyn at amr2017@med.cornell.edu.

Key Eligibility

  • Men and women greater than or equal to 18 years of age
  • Patient has confirmed Mantle Cell Lymphoma (MCL)
  • The disease has relapsed after or been refractory to at least 1 prior therapy for MCL
  • Detailed eligibility reviewed when you contact the study team

Study Details

The purpose of this study is to determine the activity of ACP-196 in subjects with relapsed or refractory MCL as measured by response rate, duration of response, progression-free survival, and time-to-next treatment.

The design and conduct of this study is supported by an understanding of the natural history and current therapies for subjects with lymphoid cancers; knowledge of the activity and safety of the first-generation Btk inhibitor (eg, ibrutinib) in subjects with hematologic cancers; and the available nonclinical and clinical information regarding ACP-196.

This study is a multicenter, open-label, randomized, parallel group study. No placebo will be administered during this study. Twenty subjects, 10 refractory and 10 relapsed, will be enrolled and will take 100 mg of ACP-196 twice per day.

This clinical trial is a Phase 2, multicenter, open-label study. Subjects will be enrolled and will take 100 mg of ACP-196 twice per day (BID) continuously for approximately 14 months. Patients will continue on treatment as long as they are responding to therapy and not experiencing unacceptable side effects.